Obstructive sleep apnoea - Alfaki presentations.

41
OBSTRUCTIVE SLEEP APNEA IN CHILDREN MOHAMED ALFAKI

Transcript of Obstructive sleep apnoea - Alfaki presentations.

Page 1: Obstructive sleep apnoea - Alfaki presentations.

OBSTRUCTIVE SLEEP APNEA

IN CHILDRENMOHAMED ALFAKI

Page 2: Obstructive sleep apnoea - Alfaki presentations.

Sleep-disordered breathing (SDB) refers to the clinical spectrum of repetitive episodes of complete or partial obstruction of the airway during sleep that disrupt nocturnal respiration and sleep architecture.

Page 3: Obstructive sleep apnoea - Alfaki presentations.

•Primary Snoring (PS)

•Snoring without obstructive apnea, frequent arousals from sleep, or gas exchange abnormalities. • Obstructive Hypoventilation Syndrome

(OHS)

•Persistent partial upper airway obstruction associated with gas exchange abnormalities, rather than discrete, cyclic apneas.

Page 4: Obstructive sleep apnoea - Alfaki presentations.

• Upper Airway Resistance Syndrome (UARS)

•Increasingly negative intrathoracic  pressures during inspiration that lead to arousals and sleep fragmentation.

Page 5: Obstructive sleep apnoea - Alfaki presentations.

•Obstructive sleep apnea (OSA)

•Disorder of breathing during sleep characterized by prolonged partial upper airway obstruction and/or intermittent complete obstruction. •Disrupts normal ventilation. •Disrupts normal sleep patterns

Page 6: Obstructive sleep apnoea - Alfaki presentations.

OSA common in young children, with a peak prevalence around 2 to 8 years, and subsequent declines in frequency.

is currently estimated to affect approximately 2% to 3% of young children..

Page 7: Obstructive sleep apnoea - Alfaki presentations.

Is scored where there is >90% drop in airflow compared to pre-event baseline for >90% of the duration of the event, lasting at least two missed breaths, with continued effort in chest and abdomen.

Page 8: Obstructive sleep apnoea - Alfaki presentations.

PHYSIOPATHOLOGY

Page 9: Obstructive sleep apnoea - Alfaki presentations.

Pathophysiology:Thus, it appears that childhood OSA is a dynamic process resulting from a combination of structural and neuromotor abnormalities rather than from structural abnormalities alone. These predisposing factors occur as part of a spectrum: In some children (e.g., those with craniofacial anomalies), structural abnormalities predominate, whereas in others (e.g., those with cerebral palsy), neuromuscular factors predominate. In otherwise healthy children with adenotonsillar hypertrophy, neuromuscular abnormalities are probably subtle.

Gozal D., Simakajornboon N., Holbrook C.R.: Secular trends in obesity and parentally reported daytime sleepiness among children referred to a pediatric sleep center for snoring and suspected sleep-disordered breathing (SDB). Sleep. 29:A74 2006

Page 10: Obstructive sleep apnoea - Alfaki presentations.
Page 11: Obstructive sleep apnoea - Alfaki presentations.
Page 12: Obstructive sleep apnoea - Alfaki presentations.

Diagnosis

Page 13: Obstructive sleep apnoea - Alfaki presentations.

DAYTIME SYMPTOMS

1. MOUTH BREATHING

2. DIFFICULTY TO WAKE UP

3. MOODINESS

4. NASAL OBSTRUCTION

5. DAYTIME SLEEPINESS

6. HYPERACTIVITY

7. COGNITIVE PROBLEMS

8. MORNING HEADACHES

Page 14: Obstructive sleep apnoea - Alfaki presentations.

NIGHTTIME SYMPTOMS AND SIGNS INCLUDE

1. SNORING

2. NOISY BREATHING & SECONDARY ENURESIS

3. PARADOXICAL CHEST AND ABDOMINAL MOTION

4. RETRACTIONS & LABORED BREATHING.

5. WITNESSED APNEA

6. SWEATING

7. RECURRING NIGHTMARES

8. OPEN THEIR MOUTHS AND HYPEREXTEND THEIR NECKS TO BREATHE.

Page 15: Obstructive sleep apnoea - Alfaki presentations.

EXAMINATION

• VITAL SIGN : HYPERTENSION• GROWTH PARAMETERS : FTT OR OBESITY• NOSE :ALLERGIC RHINITIS, NASAL POLYPS,

NASAL SEPTUM DEVIATION & ADENOIDAL FACIES.• TONSILS & HIGH-ARCHED PALATE.• MICRO OR RETROGNETHIA.• SYNDROMIC FEATURES• CVS : LOUD S2

Page 16: Obstructive sleep apnoea - Alfaki presentations.
Page 17: Obstructive sleep apnoea - Alfaki presentations.
Page 18: Obstructive sleep apnoea - Alfaki presentations.

WORKUP

PSG IS THE MAIN TOOL FOR DIAGNOSIS.PULSE OXIMETRY.OTHER SUPPORTING INVESTIGATIONABGAP AND LATERAL XR.ECHO AND ECG.BRAIN MRI .

Page 19: Obstructive sleep apnoea - Alfaki presentations.

ROLE OF PSG

• PSG IS AN IMPORTANT TOOL THAT HELPS:

1. TO CONFIRM OR EXCLUDE OSAS.2. TO DETERMINE THE SEVERITY OF

OSAS AND TREATMENT STRATEGY.3. TO EXCLUDE OTHER.

Page 20: Obstructive sleep apnoea - Alfaki presentations.
Page 21: Obstructive sleep apnoea - Alfaki presentations.
Page 22: Obstructive sleep apnoea - Alfaki presentations.
Page 23: Obstructive sleep apnoea - Alfaki presentations.

OTHER OPTION?

• OXIMETRY MAY BE USED AS A SCREENING TOOL IN SELECTED POPULATIONS BUT THERE IS NO EVIDENCES SUPPORTING THE IDEA THAT OXIMETRY ALONE CAN REPLACE PSG FOR OSAS.

• POSITIVE NOCTURNAL OXIMETRY MAY BE RELATIVELY SPECIFIC FOR OSAS, BUT NEGATIVE OXIMETRY DOES NOT EXCLUDE THE DISORDER.

Page 24: Obstructive sleep apnoea - Alfaki presentations.
Page 25: Obstructive sleep apnoea - Alfaki presentations.
Page 26: Obstructive sleep apnoea - Alfaki presentations.

Treatment

Genral measures Wt reductionAvoidance of sedativesWay of sleep

Page 27: Obstructive sleep apnoea - Alfaki presentations.

• TONSILLECTOMY AND ADENOIDECTOMY IS USUALLY THE FIRST LINE OF TREATMENT FOR PEDIATRIC OSA• (EVIDENCE QUALITY: GRADE B )

Page 28: Obstructive sleep apnoea - Alfaki presentations.
Page 29: Obstructive sleep apnoea - Alfaki presentations.
Page 30: Obstructive sleep apnoea - Alfaki presentations.
Page 31: Obstructive sleep apnoea - Alfaki presentations.
Page 32: Obstructive sleep apnoea - Alfaki presentations.

•CPAP- PATIENTS SHOULD BE REFERRED FOR CPAP

MANAGEMENT IF SYMPTOMS/ SIGNS OR OBJECTIVE EVIDENCE OF OSAS PERSISTS AFTER ADENOTONSILLECTOMY OR IF ADENOTONSILLECTOMY IS NOT PERFORMED. (EVIDENCE QUALITY: GRADE B )

Page 33: Obstructive sleep apnoea - Alfaki presentations.

• TOPICAL INTRANASAL CORTICOSTEROIDS FOR CHILDREN WITH MILD OSAS IN WHOM ADENOTONSILLECTOMY IS CONTRAINDICATED OR FOR CHILDREN WITH MILD POSTOPERATIVE OSAS. • (EVIDENCE QUALITY: GRADE B)

Page 34: Obstructive sleep apnoea - Alfaki presentations.

Pediatrics. 2012 Sep;130(3):e575-80. Goldbart AD, Greenberg-Dotan S, Tal A.

Page 35: Obstructive sleep apnoea - Alfaki presentations.

•Introduction •DS occurs in approximately 1.5 of 1000 births. •10% of mentally retarded persons.   •DS children commonly have otolaryngologic problems. 

Page 36: Obstructive sleep apnoea - Alfaki presentations.

•They also fall into the group of children with craniofacial and neurologic anomalies which predispose them to OSA. •Small midface and cranium •Relatively narrow nasopharynx •Marcroglossia •Hypotonia •Tendency for obesity •Relatively small larynx

Page 37: Obstructive sleep apnoea - Alfaki presentations.

•In addition, given their congenital heart defects, they are already predisposed to cor pulmonale. •Known complication of prolonged OSA (part of the Pickwickian syndrome).  •Because of these factors, the incidence of OSA in patients with DS has been estimated to be from 54% to 100%

Page 38: Obstructive sleep apnoea - Alfaki presentations.

•Summary •T&A is successful in the majority of patients with Down Syndrome (69%).  •More aggressive intervention such as CPAP, tracheostomy are necessary in some patients •Preoperative evaluation should include assessment for cardiac, thyroid, and cervical abnormalities. •Surgical planning should be based on the severity of disease. •Follow up sleep studies are indicated to evaluate for the need for more aggressive treatment in patients with persistent symptoms. •DS patients should be admitted post-operatively as persistent OSA and other complications are common. •ICU monitoring is often necessary

Page 39: Obstructive sleep apnoea - Alfaki presentations.
Page 40: Obstructive sleep apnoea - Alfaki presentations.

REFERENCES

• CLINICAL PRACTICE GUIDELINE DIAGNOSIS AND MANAGEMENT OF CHILDHOOD OBSTRUCTIVE SLEEP APNEA SYNDROME PEDIATRICS VOLUME 130, NUMBER 3, SEPTEMBER 2012 .

• KENDIK PEDIATRIC PULMONOLOGY• A. KADITIS ET AL. / SLEEP MEDICINE REVIEWS 27 (2016).• PEDIATRICS. 2012 SEP;130(3): MONTELUKAST FOR CHILDREN WITH

OBSTRUCTIVE SLEEP APNEA: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY.

• N ENGL J MED. 2013 MAY 21. A RANDOMIZED TRIAL OF ADENOTONSILLECTOMY FOR CHILDHOOD SLEEP APNEA.

Page 41: Obstructive sleep apnoea - Alfaki presentations.

THANKS A LOT AND HAVE ANICE DAY